SEARCH

SEARCH BY CITATION

References

  • 1
    Drossman DA, Li Z, Andruzzi E et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci 1993; 38: 156980.
  • 2
    Drossman DA, Sandler RS, McKee DC, Lovitz AJ. Bowel patterns among subjects not seeking health care. Use of a questionnaire to identify a population with bowel dysfunction. Gastroenterology 1982; 83: 52934.
  • 3
    Talley NJ, Zinsmeister AR, Van Dyke C, Melton LJ III. Epidemiology of colonic symptoms and the irritable bowel syndrome. Gastroenterology 1991; 101: 92734.
  • 4
    Jones R, Lydeard S. Irritable bowel syndrome in the general population. Br Med J 1992; 304: 8790.
  • 5
    Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Muller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut 1999; 45 (Suppl. 2): II437.
  • 6
    Foxx-Orenstein AE, Kuemmerle JF, Grider JR. Distinct 5-HT receptors mediate the peristaltic reflex induced by mucosal stimuli in human and guinea pig intestine. Gastroenterology 1996; 111: 128190.
  • 7
    Kim DY, Camilleri M. Serotonin: a mediator of the brain–gut connection. Am J Gastroenterol 2000; 95: 2698709.
  • 8
    Moss HE, Sanger GJ. The effects of granisetron, ICS 205-930 and ondansetron on the visceral pain reflex induced by duodenal distension. Br J Pharmacol 1990; 100: 497501.
  • 9
    Banner SE, Sanger GJ. Differences between 5-HT3 receptor antagonists in modulation of visceral hypersensitivity. Br J Pharmacol 1995; 114: 55862.
  • 10
    Miura M, Lawson DC, Clary EM, Mangel AW, Pappas TN. Central modulation of rectal distension-induced blood pressure changes by alosetron, a 5-HT3 receptor antagonist. Dig Dis Sci 1999; 44: 204.
  • 11
    Kozlowski CM, Green A, Grundy D, Boissonade FM, Bountra C. The 5-HT(3) receptor antagonist alosetron inhibits the colorectal distention induced depressor response and spinal c-fos expression in the anaesthetised rat. Gut 2000; 46: 47480.
  • 12
    Delvaux M, Louvel D, Mamet JP, Campos-Oriola R, Frexinos J. Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther 1998; 12: 84955.
  • 13
    Kuo B, Camilleri M, Burton D et al. Effects of 5-HT(3) antagonism on postprandial gastric volume and symptoms in humans. Aliment Pharmacol Ther 2002; 16: 22533.
  • 14
    Houghton LA, Foster JM, Whorwell PJ. Alosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers. Aliment Pharmacol Ther 2000; 14: 77582.
  • 15
    Veldhuyzen van Zanten SJ, Talley NJ, Bytzer P, Klein KB, Whorwell PJ, Zinsmeister AR. Design of treatment trials for functional gastrointestinal disorders. Gut 1999; 45 (Suppl. 2): II6977.
  • 16
    Camilleri M, Northcutt AR, Kong S, Dukes GE, McSorley D, Mangel AW. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet 2000; 355: 103540.
  • 17
    Lembo T, Wright RA, Bagby B et al. Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2001; 96: 266270.
    Direct Link:
  • 18
    Watson ME, Lacey L, Kong S et al. Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2001; 96: 4559.
    Direct Link:
  • 19
    Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 1999; 354: 1896900.
  • 20
    Juni P, Altman DG, Egger M. Systematic reviews in health care: assessing the quality of controlled clinical trials. Br Med J 2001; 323: 426.
  • 21
    Camilleri M, Mayer EA, Drossman DA et al. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther 1999; 13: 114959.
  • 22
    Camilleri M, Chey WY, Mayer EA et al. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch Intern Med 2001; 161: 173340.
  • 23
    Sterne JA, Egger M, Smith GD. Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis. Br Med J 2001; 323: 1015.
  • 24
    Jones RH, Holtmann G, Rodrigo L et al. Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients. Aliment Pharmacol Ther 1999; 13: 141927.
  • 25
    Bardhan KD, Bodemar G, Geldof H et al. A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2000; 14: 2334.
  • 26
    Tfelt-Hansen P. Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: a systematic review based on number needed to treat. Cephalalgia 1998; 18: 5328.
  • 27
    McQuay HJ, Moore RA, Eccleston C, Morley S, Williams AC. Systematic review of outpatient services for chronic pain control. Health Technol Assess 1997; 1: 1135.
  • 28
    Savoia G, Loreto M, Scibelli G. Systemic review of trials on the use of tramadol in the treatment of acute and chronic pain. Minerva Anestesiol 2000; 66: 71331.
  • 29
    Sutherland L, Roth D, Beck P, May G, Makiyama K. Oral 5-aminosalicylic acid for maintaining remission in ulcerative colitis. Cochrane Database Syst Rev 2000; 2: CD000545
  • 30
    Levine JE, Leontiadis GI, Sharma VK, Howden CW. Meta-analysis: the efficacy of intravenous H2-receptor antagonists in bleeding peptic ulcer. Aliment Pharmacol Ther 2002; 16: 113742.
  • 31
    Jailwala J, Imperiale TF, Kroenke K. Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials. Ann Intern Med 2000; 133: 13647.
  • 32
    Thompson WG, Dotevall DA, Drossman DA, Heaton KW, Kruis W. Irritable bowel syndrome: guidelines for the diagnosis. Gastroenterol Int 1989; 2: 925.
  • 33
    Viramontes BE, Camilleri M, McKinzie S, Pardi DS, Burton D, Thomforde GM. Gender-related differences in slowing colonic transit by a 5-HT3 antagonist in subjects with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2001; 96: 26716.
    Direct Link:
  • 34
    Camilleri M, Atanasova E, Carlson PJ et al. Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome. Gastroenterology 2002; 123: 42532.